Integra LifeSciences Hits 100-Patient Mark in AERA Pediatric Registry

  • Integra LifeSciences enrolled its 100th patient in the AERA Pediatric Registry, one-third of the planned 300-patient enrollment.
  • The registry evaluates the Acclarent AERA Eustachian Tube Balloon Dilation System in pediatric patients aged 8 and older.
  • AERA received FDA clearance for its pediatric indication in December 2023.
  • The registry aims to generate real-world evidence for treating obstructive Eustachian tube dysfunction (ETD) in children.

Integra LifeSciences is building real-world evidence to support the use of its AERA system in pediatric patients, a strategic move to strengthen its position in the ENT market. The registry's progress reflects the company's commitment to advancing treatment options for Eustachian tube dysfunction, a condition affecting children's ear health. This initiative aligns with broader industry trends toward personalized and evidence-based pediatric care.

Clinical Validation
How the registry data will impact the adoption of AERA in pediatric ETD treatment.
Market Positioning
Whether Integra can sustain its leadership in the ENT market through continued investment in clinical evidence.
Regulatory Dynamics
The pace at which additional FDA clearances or approvals could expand the use of AERA in pediatric patients.